130 related articles for article (PubMed ID: 11996822)
1. Pharmacokinetics of verapamil and its metabolite norverapamil from a buccal drug formulation.
Sawicki W; Janicki S
Int J Pharm; 2002 May; 238(1-2):181-9. PubMed ID: 11996822
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of verapamil and norverapamil from controlled release floating pellets in humans.
Sawicki W
Eur J Pharm Biopharm; 2002 Jan; 53(1):29-35. PubMed ID: 11777750
[TBL] [Abstract][Full Text] [Related]
3. [Bioavailability of two verapamil formulations following repeated administration in steady-state conditions. An open, two-period, crossover study].
Heintz B; Müller A; Lenhard G; Schütz M; Hutt HJ
Arzneimittelforschung; 1996 Nov; 46(11):1060-3. PubMed ID: 9065315
[TBL] [Abstract][Full Text] [Related]
4. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
Dadashzadeh S; Javadian B; Sadeghian S
Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
[TBL] [Abstract][Full Text] [Related]
5. Spline functions in convolutional modeling of verapamil bioavailability and bioequivalence. II: study in healthy volunteers.
Popović J; Mitić R; Sabo A; Mikov M; Jakovljević V; Daković-Svajcer K
Eur J Drug Metab Pharmacokinet; 2006; 31(2):87-96. PubMed ID: 16898076
[TBL] [Abstract][Full Text] [Related]
6. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
Gupta SK; Yih BM; Atkinson L; Longstreth J
J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
[TBL] [Abstract][Full Text] [Related]
7. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
Kim HJ; Choi JS
Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
[TBL] [Abstract][Full Text] [Related]
8. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of verapamil and norverapamil enantiomers after administration of immediate and controlled-release formulations to humans:evidence suggesting input-rate determined stereoselectivity.
Bhatti MM; Lewanczuk RZ; Pasutto FM; Foster RT
J Clin Pharmacol; 1995 Nov; 35(11):1076-82. PubMed ID: 8626881
[TBL] [Abstract][Full Text] [Related]
10. Opposite effect of diabetes mellitus induced by streptozotocin on oral and intravenous pharmacokinetics of verapamil in rats.
Hu N; Xie S; Liu L; Wang X; Pan X; Chen G; Zhang L; Liu H; Liu X; Liu X; Xie L; Wang G
Drug Metab Dispos; 2011 Mar; 39(3):419-25. PubMed ID: 21135265
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of verapamil and norverapamil in patients with hypertension: a comparison of oral conventional and sustained release formulations.
Jørgensen NP; Walstad RA
Pharmacol Toxicol; 1988 Aug; 63(2):105-7. PubMed ID: 3186615
[TBL] [Abstract][Full Text] [Related]
12. Effects of simvastatin on the pharmacokinetics of verapamil and its main metabolite, norverapamil, in rats.
Choi DH; Li C; Choi JS
Eur J Drug Metab Pharmacokinet; 2009; 34(3-4):163-8. PubMed ID: 20166433
[TBL] [Abstract][Full Text] [Related]
13. A steady-state evaluation of the bioavailability of chronotherapeutic oral drug absorption system verapamil PM after nighttime dosing versus immediate-acting verapamil dosed every eight hours.
Prisant LM; Devane JG; Butler J
Am J Ther; 2000 Nov; 7(6):345-51. PubMed ID: 11304641
[TBL] [Abstract][Full Text] [Related]
14. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Choi DH; Shin WG; Choi JS
Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
[TBL] [Abstract][Full Text] [Related]
15. Enhanced bioavailability of verapamil after oral administration with hesperidin in rats.
Piao YJ; Choi JS
Arch Pharm Res; 2008 Apr; 31(4):518-22. PubMed ID: 18449511
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin.
Choi DH; Chung JH; Choi JS
Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601
[TBL] [Abstract][Full Text] [Related]
17. Effect of pioglitazone on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rats.
Choi JS; Burm JP
Arch Pharm Res; 2008 Sep; 31(9):1200-4. PubMed ID: 18806964
[TBL] [Abstract][Full Text] [Related]
18. Multiple dose comparison of a whole 240 mg verapamil sustained-release tablet with two half tablets.
Moreland TA; McMurdo ME; McEwen J
Biopharm Drug Dispos; 1989; 10(3):311-9. PubMed ID: 2720134
[TBL] [Abstract][Full Text] [Related]
19. Development of novel bioadhesive buccal formulation of diltiazem: in vitro and in vivo characterization.
Shayeda ; Gannu R; Palem CR; Rao YM
PDA J Pharm Sci Technol; 2009; 63(5):401-8. PubMed ID: 20158046
[TBL] [Abstract][Full Text] [Related]
20. Distribution of verapamil and norverapamil in the eye and systemic circulation after topical administration of verapamil in rabbits.
Siegner SW; Giovanoni RL; Erickson KA; Netland PA
J Ocul Pharmacol Ther; 1998 Apr; 14(2):159-68. PubMed ID: 9572542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
